BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...
4don MSN
Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...
and plaque psoriasis. Globally, infliximab (including biosimilars) generated approximately $6.3 billion in sales in 2022, demonstrating the significant market for this therapy. However ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback